Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040323 · ClinicalTrials.gov registry record · Phase 4
Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses
A Phase 4 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 83
- Enrollment target
NCT03040323 is a Phase 4 study that was terminated before completion, run by Indiana University. The registered enrollment target is 83 participants.
The verdict
NCT03040323, a Phase 4 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 83 participants
- Enrollment target
Study Summary
The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.
Interventions
- DRUG Placebos
- DRUG Lumason 60.7Mg Powder for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2018-07-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03040323
The ClinicalTrials.gov registry entry for NCT03040323 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03040323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03040323 about?
NCT03040323 is a clinical study titled "Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses". The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.
What is the current status of trial NCT03040323?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2016-12-22. Estimated completion is 2018-07-06.
What interventions are being tested in trial NCT03040323?
The interventions under investigation include: Placebos (DRUG), Lumason 60.7Mg Powder for Injection (DRUG).
Who is sponsoring clinical trial NCT03040323?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.